The Eye Travels Wide: ProQR’s Bid For Leadership In The Genetics Of Sight
A Dutch Biotech Start-Up Launches Its Bid For Clinical Leadership In The Contested Field Of Inherited Retinal Disease
How did a youthful vendor of IT services, faced with a personal exposure to crippling illness, attract some of the best minds in biotech to launch a company with a then-untested RNA technology that today is a contender for leadership in the rarified space of inherited retinal disease? The answer may lie in the ambitiously definitive name that 36-year-old founder Daniel de Boer gave to his enterprise with a mission: ProQR – an active synonym for finding cures.
